Información del artículo
The present article is an update of the literature on pulmonary infections in patients with hematologic malignancies and in hematopoietic stem cell recipients.
A multidisciplinary group of Spanish physicians with an interest in these infections selected the most important papers produced in the field during 2005 and 2006. One of the members of the group discussed the content of each of the selected papers, with a critical review by other members of the panel.
After a review of the state of the art, papers from the fields of viral and fungal infections were discussed by the group.
Key words:
Pulmonary Infections
Respiratory Virus Infections
Fungal Infections
Hematologic Malignancies
Stem-cell Transplantation
El presente artículo es una actualización de la literatura sobre infecciones pulmonares en los pacientes con procesos hematológicos malignos y en los receptores de células madre hematopoyéticas.
Un grupo multidisciplinario de médicos españoles con interés en estas infecciones seleccionó los trabajos más importantes publicados sobre el tema durante 2005 y 2006. Un miembro del grupo discutió el contenido de cada artículo seleccionado, y otros componentes del panel efectuaron una revisión crítica del trabajo.
Después de una revisión del estado del arte, el grupo discutió los artículos sobre las infecciones víricas y micóticas.
Palabras clave:
Infecciones pulmonares
Infecciones por virus respiratorios
Infecciones fúngicas
Procesos hematológicos malignos
Trasplante de células madre
El Texto completo está disponible en PDF
References
[1.]
F. Rossini, M. Verga, P. Pioltelli, et al.
Incidence and outcome of pneumonia in patients with acute leukemia receiving first induction therapy with anthracycline- containing regimens.
Haematologica, 85 (2000), pp. 1255-1260
[2.]
G. Maschmeyer, T. Beinert, D. Buchheidt, et al.
Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients. Guidelines of the Infectious Disease Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
Ann Hematol, 82 (2003), pp. S118-S126
[3.]
G. Specchia, D. Pastore, P. Carluccio, et al.
Pneumonia in acute leukemia patients during induction therapy: experience in a single institution.
Leuk Lymphoma, 44 (2003), pp. 97-101
[4.]
G. Maschmeyer.
Pneumonia in febrile neutropenic patients: radiologic diagnosis.
Curr Opin Oncol, 13 (2001), pp. 229-235
[5.]
S.J. Lin, J. Schranz, S.M. Teutsch.
Aspergillosis case-fatality rate: systematic review of the literature.
Clin Infect Dis, 32 (2001), pp. 358-366
[6.]
J. Carratalá, B. Rosón, A. Fernández-Sevilla, F. Alcaide, F. Gudiol.
Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome.
Arch Intern Med, 158 (1998), pp. 868-872
[7.]
C.P. Heussel, H.U. Kauczor, A.J. Ullmann.
Pneumonia in neutropenic patients.
Eur Radiol, 14 (2004), pp. 256-271
[8.]
R.E. Champlin, E. Whimbey.
Community respiratory virus infections in bone marrow transplant recipients. The M. D. Anderson Cancer Center experience.
Biol Blood Marrow Transplant, 7 (2001), pp. 8S-10S
[9.]
K.L. Hicks, R.F. Chemaly, D.P. Kontoyiannis.
Community respiratory viruses in patients with cancer.
Cancer, 97 (2003), pp. 2576-2587
[10.]
P. Ljungman.
Prevention and treatment of viral infections in stem cell transplant recipients.
Br J Haematol, 118 (2002), pp. 44-57
[11.]
R. Martino, E. Ramila, N. Rabella, J.M. Munoz, M. Peyret, J.M. Portos.
Respiratory virus infection in adults with hematologic malignancies: a prospective study.
Clin Infect Dis, 36 (2003), pp. 1-8
[12.]
R. Martino, R.P. Porras, N. Rabella, J.V. Williams, E. Ramila, N. Margall, et al.
Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies.
Biol Blood Marrow Transplant, 11 (2005), pp. 781-796
[13.]
W.G. Nichols, K.A. Guthrie, L. Corey, M. Boeckh.
Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy.
Clin Infect Dis, 39 (2004), pp. 1300-1306
[14.]
S.M. Raboni, M.B. Nogueira, L.R. Tsuchiya, G.A. Takahashi, L.A. Pereira, R. Pasquini, et al.
Respiratory tract viral infections in bone marrow transplant patients.
Transplantation, 76 (2003), pp. 142-146
[15.]
M. Roghmann, K. Ball, D. Erdma, J. Lovchik, L.J. Anderson, R. Edelman.
Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation.
Bone Marrow Transplant, 32 (2003), pp. 1085-1088
[16.]
J.O. Ebbert, A.H. Limper.
Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome.
Respiration, 72 (2005), pp. 263-269
[17.]
S. Ghosh, R.E. Champlin, J. Englund, S.A. Giralt, K. Rolston, et al.
Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin.
Bone Marrow Transplant, 25 (2000), pp. 751-755
[18.]
U. Hohenthal, J. Nikoskelainen, R. Vainionpaa, R. Peltonen, M. Routamaa, M. Itala, et al.
Parainfluenza virus type 3 infections in a hematology unit.
Bone Marrow Transplant, 27 (2001), pp. 295-300
[19.]
S. McCann, J.L. Byrne, M. Rovira, P. Shaw, P. Ribaud, S. Sica, et al.
Outbreaks of infectious diseases in stem cell transplant units: a silent cause of death for patients and transplant programmes.
Bone Marrow Transplant, 33 (2004), pp. 519-529
[20.]
W.G. Nichols, T. Gooley, M. Boeckh.
Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center Experience.
Biol Blood Marrow Transplant, 7 (2001), pp. 115-155
[21.]
C. Girmenia, L. Pagano, L. Corvatta, L. Mele, A. del Favero, P. Martino.
The epidemiology of fusariosis in patients with haematological diseases. GIMEMA Infection Programme.
Br J Haematol, 11 (2000), pp. 272-276
[22.]
C.A. Kauffman.
Zygomycosis: reemergence of an old pathogen.
Clin Infect Dis, 39 (2004), pp. 588-590
[23.]
L. Pagano, M. Caira, A. Candoni, M. Offidani, L. Fianchi, B. Martino, et al.
The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study.
Haematologica, 91 (2006), pp. 1068-1075
[24.]
K.T. Yen, A.S. Lee, M.J. Krowka, et al.
Pulmonary complications in bone marrow transplantation: a practical approach to diagnosis and treatment.
Clin Chest Med, 25 (2004), pp. 189-201
[25.]
T.M. Wah, H.A. Moss, R.J. Robertson, D.L. Barnard.
Pulmonary complications following bone marrow transplantation.
Br J Radiol, 76 (2003), pp. 373-379
[26.]
R.M. Kotloff, V.N. Ahya, S.W. Crawford.
Pulmonary complications of solid organ and hematopoietic stem cell transplantation.
Am J Respir Crit Care Med, 170 (2004), pp. 22-48
[27.]
M.V. Gosselin, R.H. Adams.
Pulmonary complications in bone marrow transplantation.
J Thorac Imaging, 17 (2002), pp. 132-144
[28.]
D. Caillot, O. Casasnovas, A. Bernard, et al.
Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery.
J Clin Oncol, 15 (1997), pp. 139-147
[29.]
D. Caillot, J.F. Couaillier, A. Bernard, et al.
Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia.
J Clin Oncol, 19 (2001), pp. 253-259
[30.]
M. Subira, R. Martino, M. Rovira, L. Vázquez, D. Serrano, R. De La Cámara.
Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis.
Ann Hematol, 82 (2003), pp. 80-82
[31.]
R. Hachem, D. Sumoza, H. Hanna, E. Girgawy, M. Munsell, I. Raad.
Clinical and radiologic predictors of invasive pulmonary aspergillosis in cancer patients: should the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) criteria be revised?.
Cancer, 106 (2006), pp. 1581-1586
[32.]
B.D. Alexander.
Diagnosis of fungal infection: new technologies for the mycology laboratory.
Transp Infect Dis, 4 (2002), pp. 32-37
[33.]
S. Ascioglu, J.H. Rex, B. de Pauw, et al.
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.
Clin Infect Dis, 34 (2002), pp. 7-14
[34.]
L.J. Wheat.
Rapid diagnosis of invasive aspergillosis by antigen detection.
Transpl Infect Dis, 5 (2003), pp. 158-166
[35.]
M.A. Mennink-Kersten, J.P. Donnelly, P.E. Verweij.
Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis.
Lancet Infect Dis, 4 (2004), pp. 349-357
[36.]
K.A. Marr, S.A. Balajee, L. McLaughlin, M. Tabouret, C. Bentsen, T.J. Walsh.
Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance.
J Infect Dis, 190 (2004), pp. 641-649
[37.]
K.A. Marr, M. Laverdiere, A. Gugel, W. Leisenring.
Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay.
Clin Infect Dis, 40 (2005), pp. 1762-1769
[38.]
R. Herbrecht, V. Letscher-Bru, C. Oprea, et al.
Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients.
J Clin Oncol, 20 (2002), pp. 1898-1906
[39.]
T.J. Walsh, S. Shoham, R. Petraitiene, et al.
Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction.
J Clin Microbiol, 42 (2004), pp. 4744-4748
[40.]
A. Sulahian, S. Touratier, P. Ribaud.
False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam.
N Engl J Med, 349 (2003), pp. 2366-2367
[41.]
C.D. Pfeiffer, J.P. Fine, N. Safdar.
Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis.
Clin Infect Dis, 42 (2006), pp. 1417-1427
[42.]
Z. Odabasi, G. Mattiuzzi, E. Estey, et al.
β-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome.
Clin Infect Dis, 39 (2004), pp. 199-205
[43.]
L. Ostrosky-Zeichner, B.D. Alexander, D.H. Kett, et al.
Multicenter clinical evaluation of the (1→3) β-D-glucan assay as an aid to diagnosis of fungal infections in humans.
Clin Infect Dis, 41 (2005), pp. 654-659
[44.]
K.A. Marr.
Antifungal therapy for febrile neutropenia: issues in clinical trial design.
Curr Opin Investig Drugs, 5 (2004), pp. 202-207
[45.]
T.J. Walsh, H. Teppler, G.R. Donowitz, et al.
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
N Engl J Med, 351 (2004), pp. 1391-1402
[46.]
T.J. Walsh, P. Pappas, D.J. Winston, et al.
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
N Engl J Med, 346 (2002), pp. 225-234
[47.]
B.E. De Pauw, C.A. Sable, T.J. Walsh, et al.
Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study.
Transpl Infect Dis, 8 (2006), pp. 31-37
[48.]
C.F. Thomas, A.H. Limper.
Pneumocystis pneumonia.
N Engl J Med, 350 (2004), pp. 2487-2498
[49.]
L. Pagano, L. Fianchi, L. Mele, C. Girmenia, M. Offidani, P. Ricci, et al.
Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years’ experience of infection in GIMEMA centres.
Br J Haematol, 117 (2002), pp. 379-386
[50.]
J.R. Stringer, C.B. Beard, R.F. Miller, et al.
A new name (Pneumocystis jiroveci) for Pneumocystis from humans.
Emerg Infect Dis, 8 (2002), pp. 891-896
[51.]
M. Chabé, E. Dei-Cas, C. Creusy, et al.
Immunocompetent hosts as a reservoir of Pneumocystis organisms: histological and RT-PCR data demonstrate active replication.
Eur J Clin Microbiol Infect Dis, 23 (2004), pp. 89-97
[52.]
N.A. Maskell, D.J. Waine, A. Lindley, et al.
Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study.
Thorax, 58 (2003), pp. 594-597
[53.]
P.G. Pappas, B. Alexander, K.A. Marr, et al.
Invasive fungal infections (IFIs) in hematopoietic stem cell (HSCTs) and organ transplant recipients (OTRs): overview of the TRANSNET database.
Proceedings of the 42nd Annual Meeting of the Infectious Disease Society of America, pp. 174
[54.]
T. Saito, S. Seo, Y. Kanda, et al.
Early onset Pneumocystis carinii pneumonia after allogeneic peripheral blood stem cell transplantation.
Am J Hematol, 67 (2001), pp. 206-209
[55.]
T.K. Marras, K. Sanders, J.H. Lipton, et al.
Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation.
Transpl Infect Dis, 4 (2002), pp. 66-74
[56.]
M. Rodríguez, C.D. Sifri, J.A. Fishman.
Failure of low-dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients.
Clin Infect Dis, 38 (2004), pp. e76-e78
[57.]
D.W. Denning.
Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases.
Rev Infect Dis, 12 (1997), pp. 1147-1201
[58.]
M.M. Roden, T.E. Zaoutis, W.L. Buchanan, T.A. Knudsen, T.A. Sarkisova, R.L. Schaufele, et al.
Epidemiology and outcome of zygomycosis: a review of 929 reported cases.
Clin Infect Dis, 41 (2005), pp. 634-653
[59.]
A.H. Groll, P.M. Shah, C. Mentzel, M. Schneider, G. Just-Nuebling, K. Huebner.
Trends in the postmortem epidemiology of invasive fungal infections at a university hospital.
J Infect, 33 (1996), pp. 23-32
[60.]
T. Yamazaki, H. Kume, S. Murase, E. Yamashita, M. Arisawa.
Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan.
J Clin Microbiol, 37 (1999), pp. 1732-1738
[61.]
M.M. McNeil, S.L. Nash, R.A. Hajjeh, M.A. Phelan, L.A. Conn, B.D. Plikaytis, et al.
Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.
Clin Infect Dis, 33 (2001), pp. 641-647
[62.]
K.A. Marr, K. Seidel, T.C. White, R.A. Bowden.
Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole.
J Infect Dis, 181 (2000), pp. 309-316
[63.]
E.J. Dasbach, G.M. Davies, S.M. Teutsch.
Burden of aspergillosis-related hospitalizations in the United States.
Clin Infect Dis, 31 (2000), pp. 1524-1528
[64.]
M. Kami, U. Machida, K. Okuzumi, T. Matsumura, S. Mori Si, A. Hori, et al.
Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy.
Br J Haematol, 117 (2002), pp. 40-46
[65.]
J. Berenguer, M. Buck, F. Witebsky, F. Stock, P.A. Pizzo, T.J. Walsh.
Lysis centrifugation blood cultures in the detection of tissue proven invasive candidiasis. Disseminated versus single organ infection.
Diagn Microbiol Infect Dis, 17 (1993), pp. 103-109
[66.]
R.C. Young, J.E. Bennett, C.L. Vogel, P.P. Carbone, V.T. DeVita.
Aspergillosis. The spectrum of the disease in 98 patients.
Medicine (Baltimore), 49 (1970), pp. 147-173
[67.]
G. Chamilos, M. Luna, R.E. Lewis, G.P. Bodey, R. Chemaly, J.J. Tarrand, et al.
Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003).
Haematologica, 91 (2006), pp. 986-989
[68.]
K.A. Marr, R.A. Carter, M. Boeckh, P. Martin, L. Corey.
Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors.
Blood, 100 (2002), pp. 4358-4366
[69.]
M. Subira, R. Martino, T. Franquet, C. Puzo, A. Altes, A. Sureda, et al.
Invasive pulmonary aspergillosis in patients with hematologic malignancies: survival and prognostic factors.
Haematologica, 87 (2002), pp. 528-534
[70.]
W.J. Steinbach, D.K. Benjamin Jr, D.P. Kontoyiannis, J.R. Perfect, I. Lutsar, K.A. Marr, et al.
Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases.
Clin Infect Dis, 39 (2004), pp. 192-198
[71.]
J.J. Tarrand, M. Lichterfeld, I. Warraich, M. Luna, X.Y. Han, G.S. May, et al.
Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination.
Am J Clin Pathol, 119 (2003), pp. 854-858
[72.]
M. Akova, M. Paesmans, T. Calandra, et al.
A European Organization for Research and Treatment of Cancer-International. Antimicrobial Therapy Group Study of secondary infections in febrile, neutropenic patients with cancer.
Clin Infect Dis, 40 (2005), pp. 239-245
[73.]
W.T. Hughes, D. Armstrong, G.P. Bodey, et al.
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.
Clin Infect Dis, 34 (2002), pp. 730-751
[74.]
H. Link, A. Bohme, O.A. Cornely, et al.
Antimicrobial therapy of unexplained fever in neutropenic patients–guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever.
Ann Hematol, 82 (2003), pp. S105-S117
[75.]
J. Klastersky.
Antifungal therapy in patients with fever and neutropenia- more rational and less empirical?.
N Engl J Med, 351 (2004), pp. 1445-1447
[76.]
C.D. Pfeiffer, J.P. Fine, N. Safdar.
Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis.
Clin Infect Dis, 42 (2006), pp. 1417-1727
[77.]
M. Weisser, C. Rausch, A. Droll, et al.
Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignancies.
Clin Infect Dis, 41 (2005), pp. 1143-1149
[78.]
M. Rovira, M. Jiménez, J.P. De La Bellacasa, et al.
Detection of Aspergillus galactomannan by enzyme immunoabsorbent assay in recipients of allogeneic hematopoietic stem cell transplantation: a prospective study.
Transplantation, 77 (2004), pp. 1260-1264
[79.]
M.T. Lin, H.C. Lu, W.L. Chen.
Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer.
Clin Infect Dis, 33 (2001), pp. 1621-1627
[80.]
H. Hebart, L. Klingspor, T. Klingebiehl, et al.
PCR-based liposomal amphotericin B treatment following allogenic stem cell transplantation is a safe treatment strategy: Preliminary results of a prospective study.
American Society of Hematology, (2004), pp. P192
[81.]
R. Herbrecht, D.W. Denning, T.F. Patterson, et al.
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
N Engl J Med, 347 (2002), pp. 408-415
[82.]
E.J. Bow, J.C. Wade, D.R. Nelson.
Of yeasts and hyphae: a hematologist's approach to antifungal therapy.
ASH Annual Meeting Educational Book, (2006), pp. 361-367
[83.]
T.J. Walsh, I. Raad, T.F. Patterson, et al.
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.
Clin Infect Dis, 44 (2007), pp. 2-12
[84.]
D.W. Denning, K.A. Marr, W.M. Lau, et al.
Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.
J Infect, 53 (2006), pp. 337-349
[85.]
D. Caillot, A. Thiébaut, R. Herbrecht, S. de Botton, A. Pigneux, F. Bernard, et al.
Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial).
Cancer, 110 (2007), pp. 2740-2746
[86.]
K.A. Marr, M. Boeckh, R.A. Carter, H.W. Kim, L. Corey.
Combination antifungal therapy for invasive aspergillosis.
Clin Infect Dis, 39 (2004), pp. 797-802
[87.]
D.P. Kontoyiannis, R. Hachem, R.E. Lewis, et al.
Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies.
Cancer, 98 (2003), pp. 292-299
[88.]
J. Maertens, A. Glasmacher, R. Herbrecht, et al.
Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis.
Cancer, 107 (2006), pp. 2888-2897
[89.]
A.O. Soubani, P.H. Chandrasekar.
The clinical spectrum of pulmonary aspergillosis.
Chest, 121 (2002), pp. 1988-1999
[90.]
O.A. Cornely, J. Maertens, M. Bresnik, R. Ebrahimi, A.J. Ullmann, E. Bouza, et al.
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
Clin Infect Dis, 44 (2007), pp. 1289-1297
[91.]
J. Klastersky, M. Paesmans.
Antifungal therapy in febrile neutropenic patients: review of treatment choices and strategies for aspergillar infection.
Support Care Cancer, 15 (2007), pp. 137-141
[92.]
T.B. Aliff, P.G. Maslak, J.G. Jurcic, et al.
Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin.
Cancer, 97 (2003), pp. 1025-1032
[93.]
D.P. Kontoyiannis, R. Hachem, R.E. Lewis, et al.
Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies.
Cancer, 98 (2003), pp. 292-299
[94.]
K.A. Marr, M. Boeckh, R.A. Carter, et al.
Combination antifungal therapy for invasive aspergillosis.
Clin Infect Dis, 39 (2004), pp. 797-802
Copyright © 2008. Elsevier España S.L.. All rights reserved
